REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol 2010;596:467-88.
3. Barbero F, Russo L, Vitali M, et al. Formation of the protein corona: the interface between nanoparticles and the immune system. Semin Immunol 2017;34:52-60.
4. Mout R, Moyano DF, Rana S, Rotello VM. Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev 2012;41:2539-44.
5. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 2015;91:3-6.
6. Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol 2018;9:790.
7. Luk BT, Fang RH, Hu CMJ, Copp JA, Thamphiwatana S, et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics 2016;6:1004-11.
8. Cao H, Dan Z, He X, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 2016;10:7738-48.
9. Cao X, Hu Y, Luo S, et al. Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma. Acta pharmaceutica Sinica B 2019;9:575-89.
10. Gao C, Lin Z, Jurado-Sánchez B, et al. Stem cell membrane-coated nanogels for highly efficient in vivo tumor targeted drug delivery. Small 2016;12:4056-62.
11. Kang T, Zhu Q, Wei D, et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano 2017;11:1397-411.
12. Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A 2014;111:930-5.
13. Gao W, Hu CMJ, Fang RH, et al. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater 2013;25:3549-53.
14. Tian W, Lu J, Jiao D. Stem cell membrane vesicle-coated nanoparticles for efficient tumor-targeted therapy of orthotopic breast cancer. Polym Adv Technol 2019;30:1051-60.
15. Yaman S, Ramachandramoorthy H, Oter G, et al. Melanoma peptide MHC specific TCR expressing T-Cell membrane camouflaged PLGA nanoparticles for treatment of melanoma skin cancer. Front Bioeng Biotechnol 2020;8:943.
16. Schmid D, Park CG, Hartl CA, et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun 2017;8:1747.
17. Gao M, Liang C, Song X, et al. Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv Mater 2017;29:1701429.
18. Rao L, Bu LL, Cai B, et al. Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging. Adv Mater 2016;28:3460-6.
19. Gos M, Miloszewska J, Fau-Przybyszewska M, Przybyszewska M. Epithelial-mesenchymal transition in cancer progression. Postepy Biochem 2009;55:121-8.
20. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015;21:687-92.
21. Pandya PH, Murray ME, Pollok KE, Renbarger JL. The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res 2016;2016:4273943.
22. Kroll AV, Fang RH, Zhang L. Biointerfacing and applications of cell membrane-coated nanoparticles. Bioconjug Chem 2017;28:23-32.
23. Kroll AV, Fang RH, Jiang Y, et al. Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity. Adv Mater 2017;29. 10.1002/adma.201703969
24. Angsantikul P, Thamphiwatana S, Gao W, Zhang L. Cell membrane-coated nanoparticles as an emerging antibacterial vaccine platform. Vaccines 2015;3:814-28.
25. Fontana F, Shahbazi MA, Liu D, et al. Multistaged nanovaccines based on porous silicon@acetalated dextran@cancer cell membrane for cancer immunotherapy. Adv Mater 2017;29:1603239.
26. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 2015;125:3335-7.
27. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
28. Roybal KT, Williams JZ, Morsut L, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 2016;167:419-32.e16.
29. Schwarz KA, Leonard JN. Engineering cell-based therapies to interface robustly with host physiology. Adv Drug Deliv Rev 2016;105:55-65.
30. Roybal KT, Williams JZ, Morsut L, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 2016;167:419-32.e16.
31. Baeumler TA, Ahmed AA, Fulga TA. Engineering synthetic signaling pathways with programmable dCas9-based chimeric receptors. Cell Rep 2017;20:2639-53.
33. Son B, Lee S, Youn H, et al. The role of tumor microenvironment in therapeutic resistance. Oncotarget 2017;8:3933.
34. Paulitschke M, Nash G, Anstee D, Tanner M, Gratzer W. Pertubation of red blood cell membrane rigidity by extracellular ligands. Blood 1995;86:342-8.
35. Orbach A, Zelig O, Yedgar S, Barshtein G. Biophysical and biochemical markers of red blood cell fragility. Transfus Med Hemother 2017;44:183-7.
36. Morera D, MacKenzie SA. Is there a direct role for erythrocytes in the immune response? Vet Res 2011;42:89.
38. Mohr A, Zwacka R. The future of mesenchymal stem cell-based therapeutic approaches for cancer - from cells to ghosts. Cancer Lett 2018;414:239-49.
39. Thanuja MY, Anupama C, Ranganath SH. Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: So near and yet so far. Adv Drug Deliv Rev 2018;132:57-80.
40. von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BYS. Breaking down the barriers to precision cancer nanomedicine. Trends Biotechnol 2017;35:159-71.
41. Hu CMJ, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A 2011;108:10980-5.
42. Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of ‘marker of self’ CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010;45:67-74.
43. Dehaini D, Wei X, Fang RH, et al. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater 2017;29. 10.1002/adma.201606209
44. Ma YQ, Qin J, Plow EF. Platelet integrin αIIbβ3: activation mechanisms. J Thromb Haemost 2007;5:1345-52.
45. Fang RH, Hu CMJ, Luk BT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 2014;14:2181-8.
46. Zhang L, Li R, Chen H, et al. Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer. Int J Nanomedicine 2017;12:2129-42.
47. Bu LL, Rao L, Yu GT, et al. Cancer stem cell-platelet hybrid membrane-coated magnetic nanoparticles for enhanced photothermal therapy of head and neck squamous cell carcinoma. Adv Funct Mater 2019;29:1807733.
48. Zhang Y, Cai K, Li C, et al. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy. Nano Lett 2018;18:1908-15.
49. Jin J, Krishnamachary B, Barnett JD, et al. Human cancer cell membrane-coated biomimetic nanoparticles reduce fibroblast-mediated invasion and metastasis and induce T-cells. ACS Appl Mater Interfaces 2019;11:7850-61.
50. Felgner S, Kocijancic D, Frahm M, et al. Engineered Salmonella enterica serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy. Oncoimmunology 2017;7:e1382791.
51. Gujrati V, Kim S, Kim SH, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano 2014;8:1525-37.
52. Wang D, Dong H, Li M, et al. Erythrocyte-cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal/chemotherapy of melanoma. ACS Nano 2018;12:5241-52.
53. Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release 2016;229:130-9.
54. Hu CMJ, Fang RH, Copp J, Luk BT, Zhang L. A biomimetic nanosponge that absorbs pore-forming toxins. Nat nanotechnol 2013;8:336-40.
55. Zhu JY, Zheng DW, Zhang MK, et al. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Letters 2016;16:5895-901.
56. Spicer JD, McDonald B, Cools-Lartigue JJ, et al. Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells. Cancer Res 2012;72:3919.
57. Strell C, Lang K, Niggemann B, Zaenker KS, Entschladen F. Surface molecules regulating rolling and adhesion to endothelium of neutrophil granulocytes and MDA-MB-468 breast carcinoma cells and their interaction. Cell Mol Life Sci 2007;64:3306-16.
58. Parodi A, Quattrocchi N, van de Ven AL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 2013;8:61-8.
59. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010;16:1035-41.
60. Van Deun J, Roux Q, Deville S, et al. Feasibility of mechanical extrusion to coat nanoparticles with extracellular vesicle membranes. Cells 2020;9:1797.
61. Milne JL, Borgnia MJ, Bartesaghi A, et al. Cryo-electron microscopy-a primer for the non-microscopist. FEBS J 2013;280:28-45.
62. Parrow NL, Violet PC, Tu H, et al. Measuring deformability and red cell heterogeneity in blood by ektacytometry. J Vis Exp 2018:e56910.
63. Kuo YC, Wu HC, Hoang D, et al. Colloidal properties of nanoerythrosomes derived from bovine red blood cells. Langmuir 2016;32:171-9.
64. Deák R, Mihály J, Szigyártó IC, et al. Physicochemical characterization of artificial nanoerythrosomes derived from erythrocyte ghost membranes. Colloids Surf B Biointerfaces 2015;135:225-34.
65. Evangelopoulos M, Parodi A, Martinez JO, et al. Cell source determines the immunological impact of biomimetic nanoparticles. Biomaterials 2016;82:168-77.
66. Kaneti L, Bronshtein T, Malkah Dayan N, Kovregina I, et al. Nanoghosts as a novel natural nonviral gene delivery platform safely targeting multiple cancers. Nano letters 2016;16:1574-82.
67. Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int 2013;2013:130763.
68. Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. Int J Mol Sci 2016;17:1164.
69. Geißler S, Textor M, Kühnisch J, et al. Functional comparison of chronological and in vitro aging: differential role of the cytoskeleton and mitochondria in mesenchymal stromal cells. PLoS One 2012;7:e52700.
70. Li Q, Zhang A, Tao C, Li X, Jin P. The role of SDF-1-CXCR4/CXCR7 axis in biological behaviors of adipose tissue-derived mesenchymal stem cells in vitro. Biochem Biophys Res Commun 2013;441:675-80.
71. Kim DS, Lee MW, Ko YJ, et al. Effect of ex vivo culture density on CXCR7 expression in human mesenchymal stem cells. Int J Clin Exp Med 2016;9:10802-10.
72. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-37.
73. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
74. Park JS, Suryaprakash S, Lao YH, Leong KW. Engineering mesenchymal stem cells for regenerative medicine and drug delivery. Methods 2015;84:3-16.
75. Muzykantov VR, Murciano JC, Taylor RP, Atochina EN, Herraez A. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Analytical biochemistry 1996;241:109-19.
76. Muzykantov VR, Smirnov MD, Samokhin GP. Avidin attachment to biotinylated erythrocytes induces homologous lysis via the alternative pathway of complement. Blood 1991;78:2611-8.
77. Zaltzman A, Van den Berg C, Muzykantov V, Morgan B. Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor. Biochem J 1995;307:651-6.
78. Rennerfeldt DA, Van Vliet KJ. Concise review: when colonies are not clones: evidence and implications of intracolony heterogeneity in mesenchymal stem cells. Stem Cells 2016;34:1135-41.
79. Klimentová J, Stulík J. Methods of isolation and purification of outer membrane vesicles from gram-negative bacteria. Microbiol Res 2015;170:1-9.
80. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med 2019;4:e10143.
81. Trinidad AJ, Hong SJ, Peng Q, Madsen SJ, Hirschberg H. Combined concurrent photodynamic and gold nanoshell loaded macrophage-mediated photothermal therapies: an in vitro study on squamous cell head and neck carcinoma. Lasers Surg Med 2014;46:310-8.
82. Bahmani B, Bacon D, Anvari B. Erythrocyte-derived photo-theranostic agents: hybrid nano-vesicles containing indocyanine green for near infrared imaging and therapeutic applications. Sci Rep 2013;3:2180.
83. Baek SK, Makkouk AR, Krasieva T, et al. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neurooncol 2011;104:439-48.
84. Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73:2412-7.
85. Pasto A, Giordano F, Evangelopoulos M, Amadori A, Tasciotti E. Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy. Clin Transl Med 2019;8:8.
86. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012;1:1074-83.
87. Xuan M, Shao J, Dai L, He Q, Li J. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthc Mater 2015;4:1645-52.
88. Thamphiwatana S, Angsantikul P, Escajadillo T, et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc Natl Acad Sci U S A 2017;114:11488-93.
89. Krishnamurthy S, Gnanasammandhan MK, Xie C, et al. Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. Nanoscale 2016;8:6981-5.
90. Xue J, Zhao Z, Zhang L, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol 2017;12:692-700.
91. Wang F, Fang RH, Luk BT, et al. Nanoparticle-based antivirulence vaccine for the management of methicillin-resistant staphylococcus aureus skin infection. Adv Mater 2016;26:1628-35.
92. Wang C, Sun W, Ye Y, et al. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat Biomed Eng 2017;1:11.
93. Li J, Sharkey CC, Wun B, Liesveld JL, King MR. Genetic engineering of platelets to neutralize circulating tumor cells. J Control Release 2016;228:38-47.
94. Hu Q, Qian C, Sun W, et al. Engineered nanoplatelets for enhanced treatment of multiple myeloma and thrombus. Adv Mater 2016;28:9573-80.
95. Sadhukha T, O’Brien TD, Prabha S. Nano-engineered mesenchymal stem cells as targeted therapeutic carriers. J Control Release 2014;196:243-51.
96. Wang X, Gao J, Ouyang X, et al. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. Int J Nanomedicine 2018;13:5231-48.
97. Sun H, Su J, Meng Q, et al. Cancer cell membrane-coated gold nanocages with hyperthermia-triggered drug release and homotypic target inhibit growth and metastasis of breast cancer. Adv Funct Mater 2017;27:1604300.
98. Kim OY, Park HT, Dinh NTH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun 2017;8:626.
99. Fantappiè L, de Santis M, Chiarot E, et al. Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen. J Extracell Vesicles 2014;3. 10.3402/jev.v3.24015
100. Stephan MT, Stephan SB, Bak P, Chen J, Irvine DJ. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 2012;33:5776-87.
101. Xie Z, Su Y, Kim GB, et al. Immune cell-mediated biodegradable theranostic nanoparticles for melanoma targeting and drug delivery. Small 2017;13:1603121.
102. Guilliams M, Ginhoux F, Jakubzick C, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol 2014;14:571-8.
103. Fossati G, Ricevuti G, Edwards SW, et al. Neutrophil infiltration into human gliomas. Acta Neuropathol 1999;98:349-54.
104. Fang RH, Kroll AV, Gao W, Zhang L. Cell membrane coating nanotechnology. Adv Mater 2018;30:1706759.
105. Danesh A, Inglis HC, Jackman RP, et al. Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro. Blood 2014;123:687-96.
107. Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 2018;33:965-83.
108. Li J, Ai Y, Wang L, et al. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials 2016;76:52-65.
109. Wu HH, Zhou Y, Tabata Y, Gao JQ. Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release 2019;294:102-13.
110. Kuriakose AE, Nguyen TP, Noukeu LC, et al. Stem cells as drug delivery vehicles. Encyclopedia of tissue engineering and regenerative medicine. Oxford: Academic Press; 2019. pp. 197-210.
112. Lee EY, Bang JY, Park GW, et al. Global proteomic profiling of native outer membrane vesicles derived from Escherichia coli. Proteomics 2007;7:3143-53.
113. Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev 2005;19:2645-55.
114. Gao W, Fang RH, Thamphiwatana S, et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano letters 2015;15:1403-9.
115. Muralinath M, Kuehn MJ, Roland KL, Curtiss R 3rd. Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect Immun 2011;79:887-94.
116. Sick E, Jeanne A, Schneider C, et al. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol 2012;167:1415-30.
117. Lee JY, Vyas CK, Kim GG, et al. Red blood cell membrane bioengineered Zr-89 labelled hollow mesoporous silica nanosphere for overcoming phagocytosis. Sci Rep 2019;9:7419.
118. Othman M, Emsley J. Gene of the issue: GP1BA gene mutations associated with bleeding. Platelets 2017;28:832-6.
119. Li R, Emsley J. The organizing principle of the platelet glycoprotein Ib-IX-V complex. J Thromb Haemost 2013;11:605-14.
120. Erpenbeck L, Nieswandt B, Schön M, Pozgajova M, Schön MP. Inhibition of platelet GPIbα and promotion of melanoma metastasis. J Investig Dermatol 2010;130:576-86.
121. Malehmir M, Pfister D, Gallage S, et al. Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 2019;25:641-55.
123. Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 1998;395:347-53.
124. Scales SJ, Hesser BA, Masuda ES, Scheller RH. Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly. J Biol Chem 2002;277:28271-9.
125. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818.
126. Kube S, Hersch N, Naumovska E, et al. Fusogenic liposomes as nano carriers for delivery of intracellular proteins. Langmuir 2017;33:1051-9.
127. Han J, Pluhackova K, Böckmann RA. The multifaceted role of SNARE proteins in membrane fusion. Front Physiol 2017;8:5.
128. East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta Gen Subj 2002;1572:364-86.
130. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
131. Miller JL, deWet BJM, Martinez-Pomares L, et al. The mannose receptor mediates dengue virus infection of macrophages. PLOS Pathogens 2008;4:e17.
132. Sukegawa S, Miyagi E, Bouamr F, Farkašová H, Strebel K. Mannose receptor 1 restricts HIV particle release from infected macrophages. Cell Rep 2018;22:786-95.
133. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
135. Panés J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999;126:537-50.
136. Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc Res 1996;32:733-42.
137. Huang Y, Gao X, Chen J. Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. Acta pharmaceutica Sinica B 2018;8:4-13.
138. Mitchell MJ, King MR. Leukocytes as carriers for targeted cancer drug delivery. Expert Opin Drug Deliv 2015;12:375-92.
139. Huang R, Li X, He Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol 2020;13:86.
140. Crittenden M, Gough M, Chester J, et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 2003;63:3173-80.
141. Ma W, Zhu D, Li J, et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics 2020;10:1281-95.
142. Atsuhiro M, Masaru Y, Hideyuki S, et al. Role of Fc receptors as a therapeutic target. Inflamm Allergy Drug Targets 2009;8:80-6.
143. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998;95:652-6.
144. Tan Sardjono C, Mottram PL, Hogarth PM. The role of FcgammaRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus. Immunol Cell Biol 2003;81:374-81.
145. Patten DA. SCARF1: a multifaceted, yet largely understudied, scavenger receptor. Inflamm Res 2018;67:627-32.
146. Païdassi H, Tacnet-Delorme P, Garlatti V, et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 2008;180:2329-38.
147. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
148. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
149. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
150. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
151. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815.
152. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
153. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000;7:1166-73.
154. Jiang X, Fitch S, Wang C, et al. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery. Proc Natl Acad Sci U S A 2016;113:13857-62.
155. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765-72.
156. Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002;169:5538.
157. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739-45.
158. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
159. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer discovery 2013;3:1355-63.
160. Sheng Z, Zhu X, Sun Y, Zhang Y. The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. Oncotarget 2017;8:57826-35.
161. Xu S, Cui F, Huang D, et al. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. Int J Nanomedicine 2018;14:17-32.
162. Zhang X, Wang C, Wang J, et al. PD-1 blockade cellular vesicles for cancer immunotherapy. Adv Mater 2018;30:1707112.
163. Wieczorek M, Abualrous ET, Sticht J, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol 2017;8:292.
164. Alberts B, Johnson A, Lewis J, et al. T cells and MHC proteins. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002.
165. Fernando MMA, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008;4:e1000024.
166. Espel E, Garcia-Sanz JA, Aubert V, et al. Transcriptional and translational control of TNF-α gene expression in human monocytes by major histocompatibility complex class II ligands. Eur J Immunol 1996;26:2417-24.
167. Donati B, Lorenzini E, Ciarrocchi A. BRD4 and cancer: going beyond transcriptional regulation. Mol Cancer 2018;17:164.
168. Da Costa D, Agathanggelou A, Perry T, et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J 2013;3:e126.
169. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
170. Crawford NPS, Alsarraj J, Lukes L, et al. Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci 2008;105:6380.
171. Ding N, Hah N, Yu RT, et al. BRD4 is a novel therapeutic target for liver fibrosis. Proc Natl Acad Sci 2015;112:15713.
172. Tang X, Peng R, Ren Y, et al. BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis. Mol Pharmacol 2012;83. mol.112.081661
173. Zhou B, Mu J, Gong Y, et al. Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression. Redox biol 2017;11:390-402.
174. Ai X, Wang S, Duan Y, et al. Emerging approaches to functionalizing cell membrane-coated nanoparticles. Biochemistry 2020. doi: 10.1021/acs.biochem.0c00343
175. Fang RH, Hu CMJ, Chen KNH, et al. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 2013;5:8884-8.
176. Zhang Z, Qian H, Huang J, et al. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment. Int J Nanomedicine 2018;13:4961-75.
177. Chen H, Sha H, Zhang L, et al. Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein. Int J Nanomedicine 2018;13:5347-59.
178. Liu L, He H, Liu J. Advances on non-genetic cell membrane engineering for biomedical applications. Polymers 2019;11:2017.
179. Krishnamurthy S, Muthukumaran P, Jayakumar MKG, et al. Surface protein engineering increases the circulation time of a cell membrane-based nanotherapeutic. Nanomedicine 2019;18:169-78.
180. Leth-Larsen R, Lund RR, Ditzel HJ. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics 2010;9:1369-82.
181. Saeui CT, Mathew MP, Liu L, Urias E, Yarema KJ. Cell surface and membrane engineering: emerging technologies and applications. J Funct Biomater 2015;6:454-85.
